Physician profile
Heather A Steele
NPI 1538209606
$2,565.91
in general payments reported to CMS, 2019-2025
38 companies · $591 in 2025
The $591 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $43.91 · 2021: $33.99 · 2022: $185 · 2023: $898 · 2024: $611 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.52 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $477.03 | 2019-2025 | |
| Janssen Biotech, INC. | $292.55 | 2019-2025 | Carvykti, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals LP | $259.36 | 2020-2025 | Imfinzi, Enhertu, Calquence |
| Eisai INC. | $196.04 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $151.23 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $121.99 | 2023 | Rezlidhia, Tavalisse |
| Bayer Healthcare Pharmaceuticals INC. | $111.44 | 2023 | |
| Emd Serono, INC. | $89.24 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $79.68 | 2020-2023 | Reblozyl |
| Merck Sharp & Dohme LLC | $71.87 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $63.29 | 2022-2023 | Imbruvica |
| Amgen INC. | $43.02 | 2020-2023 | Nplate, Vectibix, Xgeva |
| Incyte Corporation | $40.71 | 2023-2025 | Monjuvi, Zynyz, Jakafi |
| Janssen Pharmaceuticals, INC | $38.60 | 2019 | |
| Pharmacosmos Therapeutics INC. | $32.99 | 2025 | Monoferric |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $31.01 | 2025 | Xtandi |
| Dendreon Pharmaceuticals LLC | $30.88 | 2025 | Provenge |
| Adc Therapeutics America, INC. | $30.08 | 2025 | |
| Beone Medicines USA, INC. | $27.31 | 2025 | Brukinsa |
| Celgene Corporation | $26.23 | 2023-2025 | Reblozyl, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $24.95 | 2024 | Alunbrig |
| Lilly USA, LLC | $23.57 | 2024 | Jaypirca, Retevmo, Verzenio |
| Daiichi Sankyo INC. | $23.13 | 2024 | Enhertu |
| Jazz Pharmaceuticals INC. | $22.89 | 2025 | |
| Genzyme Corporation | $22.88 | 2022 | |
| Leo Pharma INC. | $22.58 | 2025 | Adbry |
| Array Biopharma INC | $22.37 | 2023 | Braftovi, Mektovi, Lorbrena |
| Abbvie INC. | $20.06 | 2025 | |
| Novocure INC. | $19.93 | 2019 | |
| Beigene USA, INC. | $19.29 | 2021 | |
| Nuvation Bio INC. | $19.14 | 2025 | Ibtrozi |
| Blueprint Medicines Corporation | $18.98 | 2024 | Ayvakit |
| Morphosys, US INC. | $16.53 | 2023 | Monjuvi |
| Global Blood Therapeutics, INC. | $15.99 | 2022 | |
| Deciphera Pharmaceuticals INC. | $15.68 | 2023 | Qinlock |
| Sumitomo Pharma America, INC. | $15.34 | 2025 | Orgovyx |
| G1 Therapeutics, INC. | $14.07 | 2023 | Cosela |
| Seagen INC. | $13.98 | 2023 | Padcev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.